The Latin America, Middle East and Africa Left Atrial Appendage (LAA) Closure Device Market should witness market growth of 26.1% CAGR during the forecast period (2022-2028).
The most dreaded consequence of atrial fibrillation is a thromboembolic event resulting in a cerebrovascular disaster (CVA). Oral anticoagulant (AC) medication and left atrial appendage (LAA) ligation or excision are the two basic strategies for avoiding stroke in people with atrial fibrillation. LAA devices intended to lower the risk of thromboembolism from the left atrial appendage (LAA) among patients with non-valvular atrial fibrillation are implanted in the heart.
To prevent the LAA thrombus from reaching the systemic circulation, the apparatus mechanically occludes the LAA. Numerous organizations, both new and old, highlight the improving safety of left atrial appendage (LAA) closure devices. In addition, the rapidly increasing use of advanced and cutting-edge technologies in the left atrial appendage closure device market is anticipated to increase sales and profits throughout.
In recent years, the left atrial appendage (LAA) device market has witnessed a rapid expansion as a result of the rapid evolution of clinical expertise, implant effectiveness, and procedural safety, which has led to a rapid increase in the market size of left atrial appendage (LAA) closure devices. Percutaneous occlusion is a very recent and developing technology that is commonly advised for individuals with atrial fibrillation and an elevated risk of stroke.
The UAE healthcare industry has developed to satisfy the population's changing requirements and the country's aspiration to become a regional medical tourism hub. The COVID-19 outbreak has prompted the UAE to recommit to healthcare investment. Due to this, the adoption of left atrial appendage closure devices would also be expedited within healthcare facilities across the country. This factor is increasing the growth of the regional left atrial appendage closure devices market.
The Brazil market dominated the LAMEA Left Atrial Appendage (LAA) Closure Device Market by Country in 2021; thereby, achieving a market value of $88.6 million by 2028. The Argentina market is poised to grow at a CAGR of 26.8% during (2022-2028). Additionally, The UAE market should witness a CAGR of 25.7% during (2022-2028).
Based on Application, the market is segmented into Geospatial Mapping, Disaster Management, Energy & Resource Management, Surveillance & Monitoring, and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Johnson & Johnson (Johnson & Johnson Services, Inc.), Occlutech Holding AG, LifeTech Scientific Corporation, Cardia, Inc. and Lepu Medical Technology Co., Ltd
The most dreaded consequence of atrial fibrillation is a thromboembolic event resulting in a cerebrovascular disaster (CVA). Oral anticoagulant (AC) medication and left atrial appendage (LAA) ligation or excision are the two basic strategies for avoiding stroke in people with atrial fibrillation. LAA devices intended to lower the risk of thromboembolism from the left atrial appendage (LAA) among patients with non-valvular atrial fibrillation are implanted in the heart.
To prevent the LAA thrombus from reaching the systemic circulation, the apparatus mechanically occludes the LAA. Numerous organizations, both new and old, highlight the improving safety of left atrial appendage (LAA) closure devices. In addition, the rapidly increasing use of advanced and cutting-edge technologies in the left atrial appendage closure device market is anticipated to increase sales and profits throughout.
In recent years, the left atrial appendage (LAA) device market has witnessed a rapid expansion as a result of the rapid evolution of clinical expertise, implant effectiveness, and procedural safety, which has led to a rapid increase in the market size of left atrial appendage (LAA) closure devices. Percutaneous occlusion is a very recent and developing technology that is commonly advised for individuals with atrial fibrillation and an elevated risk of stroke.
The UAE healthcare industry has developed to satisfy the population's changing requirements and the country's aspiration to become a regional medical tourism hub. The COVID-19 outbreak has prompted the UAE to recommit to healthcare investment. Due to this, the adoption of left atrial appendage closure devices would also be expedited within healthcare facilities across the country. This factor is increasing the growth of the regional left atrial appendage closure devices market.
The Brazil market dominated the LAMEA Left Atrial Appendage (LAA) Closure Device Market by Country in 2021; thereby, achieving a market value of $88.6 million by 2028. The Argentina market is poised to grow at a CAGR of 26.8% during (2022-2028). Additionally, The UAE market should witness a CAGR of 25.7% during (2022-2028).
Based on Application, the market is segmented into Geospatial Mapping, Disaster Management, Energy & Resource Management, Surveillance & Monitoring, and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Johnson & Johnson (Johnson & Johnson Services, Inc.), Occlutech Holding AG, LifeTech Scientific Corporation, Cardia, Inc. and Lepu Medical Technology Co., Ltd
Scope of the Study
By End-use
- Hospital
- Ambulatory Surgery Centers
- Others
By Product
- Endocardial LAA Devices
- Epicardial LAA Devices
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Boston Scientific Corporation
- AtriCure, Inc.
- Abbott Laboratories
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Occlutech Holding AG
- LifeTech Scientific Corporation
- Cardia, Inc.
- Lepu Medical Technology Co., Ltd
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Left Atrial Appendage (LAA) Closure Device Market by End-use
Chapter 4. LAMEA Left Atrial Appendage (LAA) Closure Device Market by Product
Chapter 5. LAMEA Left Atrial Appendage (LAA) Closure Device Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- AtriCure, Inc.
- Abbott Laboratories
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Occlutech Holding AG
- LifeTech Scientific Corporation
- Cardia, Inc.
- Lepu Medical Technology Co., Ltd
Methodology
LOADING...
